Impaired balance [sosy]
Procoagulant [aapp, bacs]
Anticoagulant [phsu]
hormone replacement [topp]
therapy [ftcn]
placebo controlled study [inpr, resa]
placebo controlled study [inpr, resa]
Health [idcn]
postmenopausal [tmco]
Women [popg]
Received [qlco]
placebo [topp]
N NOS [aapp, imft]
Daily [tmco]
mg% [qnco]
Estradiol [horm, phsu, strd]
N NOS [aapp, imft]
Group [idcn]
Combined [qlco]
Progestagen [horm, phsu, strd]
days [tmco]
Cycle [tmco]
N NOS [aapp, imft]
E-2-P [orch, phsu]
Group [idcn]
Compared [acty]
placebo [topp]
Plasma [bdsu]
ATIII [aapp, phsu]
Reduced [qlco]
Group [idcn]
Plasma [bdsu]
Protein C [aapp, bacs, phsu]
Decreased [qnco]
E-2-P [orch, phsu]
Group [idcn]
Plasma [bdsu]
Protein S [aapp, bacs]
Decreased [qnco]
E-2-P [orch, phsu]
Group [idcn]
E-2-P [orch, phsu]
Group [idcn]
Plasma [bdsu]
Factor VII [aapp, bacs, phsu]
Antigen [imft]
activity [dora]
Borderline [qlco]
Observed [ftcn]
In [qnco]
Active [ftcn]
Factor VII [aapp, bacs, phsu]
Plasma [bdsu]
Tissue-Type Plasminogen Activator [aapp, enzy, phsu]
Plasminogen Activator, Urokinase [aapp, enzy, phsu]
Plasminogen Activator Inhibitor Type 1 [aapp, bacs]
Decreased [qnco]
E-2-P [orch, phsu]
Group [idcn]
Plasminogen [aapp, bacs, phsu]
Increased [qnco]
treatment [ftcn]
Levels [qlco]
Prothrombin fragment 1+2 [aapp, bacs]
Levels [qlco]
Thrombin-antithrombin complex [aapp, enzy]
III [inpr]
Plasmin [aapp, enzy, phsu]
alpha-2-Antiplasmin [aapp, bacs, phsu]
Complexes [chvs]
Fibrin [aapp, bacs, phsu]
Ogen [horm, phsu, strd]
degradation [ftcn]
Products [enty]
Short-term [tmco]
E-2-P [orch, phsu]
treatment [ftcn]
Shift [ftcn]
Procoagulant [aapp, bacs]
Anticoagulant [phsu]
Balance [orgf]
Procoagulant [aapp, bacs]
State [geoa]
Proportion [qnco]
Women [popg]
Reticular [spco]
fibrinolytic [topp]
activity [dora]
Relevant [qlco]
Increased [qnco]
Venous Thromboembolism [patf]
ERT [topp]
HRT [topp]
Possibly [qlco]
Negative [qlco]
Heart [bpoc]
Estrogen Replacement [topp]
Progestin [horm, phsu, strd]
Study [mnob]
